News Release 17-Dec-2024
"EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)."
www.eurekalert.org/news-release...
"EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)."
www.eurekalert.org/news-release...
December 18, 2024 at 12:29 PM
News Release 17-Dec-2024
"EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)."
www.eurekalert.org/news-release...
"EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)."
www.eurekalert.org/news-release...
🚀 Big news in the fight against Epstein-Barr virus (EBV):
Start-up #EBViously, a spin-off from #HelmholtzMunich and the German Center for Infection Research (DZIF) @dzif.bsky.social, is officially launched!
👉 t1p.de/bgfbs
#Vaccine #Virus #EBV #Healthcare #Innovation #Startups #SpinOff #DZIF
Start-up #EBViously, a spin-off from #HelmholtzMunich and the German Center for Infection Research (DZIF) @dzif.bsky.social, is officially launched!
👉 t1p.de/bgfbs
#Vaccine #Virus #EBV #Healthcare #Innovation #Startups #SpinOff #DZIF
December 16, 2024 at 2:25 PM
🚀 Big news in the fight against Epstein-Barr virus (EBV):
Start-up #EBViously, a spin-off from #HelmholtzMunich and the German Center for Infection Research (DZIF) @dzif.bsky.social, is officially launched!
👉 t1p.de/bgfbs
#Vaccine #Virus #EBV #Healthcare #Innovation #Startups #SpinOff #DZIF
Start-up #EBViously, a spin-off from #HelmholtzMunich and the German Center for Infection Research (DZIF) @dzif.bsky.social, is officially launched!
👉 t1p.de/bgfbs
#Vaccine #Virus #EBV #Healthcare #Innovation #Startups #SpinOff #DZIF
„EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective preventive vaccine against a range of diseases caused by Epstein-Barr virus“
idw-online.de/de/news812138
idw-online.de/de/news812138
January 9, 2024 at 12:23 AM
„EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective preventive vaccine against a range of diseases caused by Epstein-Barr virus“
idw-online.de/de/news812138
idw-online.de/de/news812138
Related to ME/CFS
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich,
www.eurekalert.org/news-release...
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich,
www.eurekalert.org/news-release...
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr ...
www.eurekalert.org
December 19, 2024 at 1:22 PM
Related to ME/CFS
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich,
www.eurekalert.org/news-release...
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich,
www.eurekalert.org/news-release...
EBViously startet! Das Spin-off von @www.helmholtz-munich.de entwickelt einen Impfstoff gegen das Epstein-Barr-Virus (EBV), das mit Krankheiten wie Pfeiffersches Drüsenfieber, ME/CFS, MS und bestimmten Krebsarten in Verbindung steht.
#EBV #Innovation
👉https://t1p.de/r48ld
#EBV #Innovation
👉https://t1p.de/r48ld
December 16, 2024 at 1:52 PM
EBViously startet! Das Spin-off von @www.helmholtz-munich.de entwickelt einen Impfstoff gegen das Epstein-Barr-Virus (EBV), das mit Krankheiten wie Pfeiffersches Drüsenfieber, ME/CFS, MS und bestimmten Krebsarten in Verbindung steht.
#EBV #Innovation
👉https://t1p.de/r48ld
#EBV #Innovation
👉https://t1p.de/r48ld
Don't worry, our laboratories over here are still working on vaccines like these, with many in trial stages ahead of Moderna (like EBViously for Epstein-Barr). The "only" (well, hardest) thing you have to do, is get a sane government again...
February 13, 2026 at 2:29 PM
Don't worry, our laboratories over here are still working on vaccines like these, with many in trial stages ahead of Moderna (like EBViously for Epstein-Barr). The "only" (well, hardest) thing you have to do, is get a sane government again...
Better yet, some of these candidates are being tested in clinical trials to address the long-term sequelae of EBV infection:
- Moderna mRNA-1195 for multiple sclerosis.
- EBViously EBV-001 for multiple sclerosis, certain cancers, and even ME/CFS.
- British and HK MVA-EL for certain cancers.
- Moderna mRNA-1195 for multiple sclerosis.
- EBViously EBV-001 for multiple sclerosis, certain cancers, and even ME/CFS.
- British and HK MVA-EL for certain cancers.
November 26, 2025 at 3:54 PM
Better yet, some of these candidates are being tested in clinical trials to address the long-term sequelae of EBV infection:
- Moderna mRNA-1195 for multiple sclerosis.
- EBViously EBV-001 for multiple sclerosis, certain cancers, and even ME/CFS.
- British and HK MVA-EL for certain cancers.
- Moderna mRNA-1195 for multiple sclerosis.
- EBViously EBV-001 for multiple sclerosis, certain cancers, and even ME/CFS.
- British and HK MVA-EL for certain cancers.
Press release:
EBViously Presents Novel In-Vitro Data Demonstrating Potent
Infection Prevention of its Vaccine Candidate EBV-001
www.globenewswire.com/news-release...
“EBV-001 is designed for the prevention of EBV-induced diseases via high titers of potent, neutralizing
antibodies”
EBViously Presents Novel In-Vitro Data Demonstrating Potent
Infection Prevention of its Vaccine Candidate EBV-001
www.globenewswire.com/news-release...
“EBV-001 is designed for the prevention of EBV-induced diseases via high titers of potent, neutralizing
antibodies”
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Cand...
Presentation at the World Vaccine Congress West Coast2023EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high...
www.globenewswire.com
December 5, 2023 at 3:38 PM
Press release:
EBViously Presents Novel In-Vitro Data Demonstrating Potent
Infection Prevention of its Vaccine Candidate EBV-001
www.globenewswire.com/news-release...
“EBV-001 is designed for the prevention of EBV-induced diseases via high titers of potent, neutralizing
antibodies”
EBViously Presents Novel In-Vitro Data Demonstrating Potent
Infection Prevention of its Vaccine Candidate EBV-001
www.globenewswire.com/news-release...
“EBV-001 is designed for the prevention of EBV-induced diseases via high titers of potent, neutralizing
antibodies”
"Der Markt bei Infektionskrankheiten ist schwierig. Und mit Impfstoffen wird es dann noch komplizierter." EBViously hat es mit seinem Epstein-Barr-Impfstoff erlebt, insbesondere hinsichtlich der GMP-konformen Produktion… — @insertcaffeine.bsky.social erzählt mehr: www.laborjournal.de/editorials/3...
January 23, 2025 at 3:38 PM
"Der Markt bei Infektionskrankheiten ist schwierig. Und mit Impfstoffen wird es dann noch komplizierter." EBViously hat es mit seinem Epstein-Barr-Impfstoff erlebt, insbesondere hinsichtlich der GMP-konformen Produktion… — @insertcaffeine.bsky.social erzählt mehr: www.laborjournal.de/editorials/3...
While we don't have a licensed EBV vaccine yet, several vaccine candidates are currently in development:
- mRNA vaccine by Moderna
- Nanoparticle vaccine by the NIH
- VLP vaccine by EBViously
- Viral vector vaccine by UK and Hong Kong scientists
Figure source: Dai et al. (2025), Viruses
- mRNA vaccine by Moderna
- Nanoparticle vaccine by the NIH
- VLP vaccine by EBViously
- Viral vector vaccine by UK and Hong Kong scientists
Figure source: Dai et al. (2025), Viruses
November 26, 2025 at 3:54 PM
While we don't have a licensed EBV vaccine yet, several vaccine candidates are currently in development:
- mRNA vaccine by Moderna
- Nanoparticle vaccine by the NIH
- VLP vaccine by EBViously
- Viral vector vaccine by UK and Hong Kong scientists
Figure source: Dai et al. (2025), Viruses
- mRNA vaccine by Moderna
- Nanoparticle vaccine by the NIH
- VLP vaccine by EBViously
- Viral vector vaccine by UK and Hong Kong scientists
Figure source: Dai et al. (2025), Viruses
Start-up EBViously gegründet:
Das Unternehmen entwickelt einen Impfstoff gegen EBV. Ziel ist es, Menschen vor einer Reihe schwerer Erkrankungen sowie Folgeerkrankungen wie Multiple Sklerose und #MECFS und vor bestimmten Krebsarten zu schützen.
www.dzif.de/de/start-ebv...
Das Unternehmen entwickelt einen Impfstoff gegen EBV. Ziel ist es, Menschen vor einer Reihe schwerer Erkrankungen sowie Folgeerkrankungen wie Multiple Sklerose und #MECFS und vor bestimmten Krebsarten zu schützen.
www.dzif.de/de/start-ebv...
Start-up EBViously gegründet | Deutsches Zentrum für InfektionsforschungMenüMenüSucheSucheE-MailE-MailE-MailVorherigeWeiterE-Mail
EBViously, ein Spin-off von Helmholtz Munich, hat am 11. November 2024 offiziell seine Tätigkeit aufgenommen.
www.dzif.de
December 17, 2024 at 10:37 AM
Start-up EBViously gegründet:
Das Unternehmen entwickelt einen Impfstoff gegen EBV. Ziel ist es, Menschen vor einer Reihe schwerer Erkrankungen sowie Folgeerkrankungen wie Multiple Sklerose und #MECFS und vor bestimmten Krebsarten zu schützen.
www.dzif.de/de/start-ebv...
Das Unternehmen entwickelt einen Impfstoff gegen EBV. Ziel ist es, Menschen vor einer Reihe schwerer Erkrankungen sowie Folgeerkrankungen wie Multiple Sklerose und #MECFS und vor bestimmten Krebsarten zu schützen.
www.dzif.de/de/start-ebv...
ME/CFS related:
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich,
www.eurekalert.org/news-release...
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich,
www.eurekalert.org/news-release...
December 19, 2024 at 1:27 PM
ME/CFS related:
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich,
www.eurekalert.org/news-release...
Start-up EBViously founded
EBViously, a spin-off of Helmholtz Munich,
www.eurekalert.org/news-release...